|
業務類別
|
Biotechnology |
|
業務概覽
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
| 公司地址
| 2656 State Street, Carlsbad, CA, USA, 92008 |
| 電話號碼
| +1 619 728-4760 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tyra.bio |
| 員工數量
| 87 |
| Dr. Douglas J. Warner, M.D. |
Chief Medical Officer |
美元 165.63K |
18/04/2025 |
| Dr. Todd Harris, PhD |
President, Chief Executive Officer and Director |
美元 632.70K |
02/03/2026 |
| Mr. Bhavesh Ashar, M.B.A. |
Chief Operating Officer |
-- |
01/12/2025 |
| Mr. Alan Fuhrman |
Chief Financial Officer and Principal Accounting Officer |
-- |
02/03/2026 |
| Mr. Daniel Bensen |
Chief Discovery Officer |
美元 475.90K |
01/12/2025 |
|
|
| Dr. Gilla Kaplan,PhD |
Independent Director |
02/03/2026 |
| Dr. S. Michael Rothenberg, M.D.,PhD |
Independent Director |
02/03/2026 |
| Mr. Robert J. More |
Chairman of the Board |
02/03/2026 |
| Dr. Todd Harris, PhD |
President, Chief Executive Officer and Director |
02/03/2026 |
| Ms. Adele M. Gulfo |
Independent Director |
02/03/2026 |
| Dr. Susan Moran, M.D. |
Independent Director |
02/03/2026 |
| Dr. Jake Simson, PhD |
Independent Director |
02/03/2026 |
| Mr. Rehan Verjee |
Independent Director |
02/03/2026 |
| Dr. Melissa McCracken, PhD |
Independent Director |
02/03/2026 |
|
|
|
|
